Want to join the conversation?
$BIIB 2Q15 Call: Global TECFIDERA revenue increased 26% YoverY; revenues consisted of $721MM in US and $163MM outside US. Ex-US TECFIDERA sales decreased 8% vs. 1Q15. Interferon revenues, including AVONEX and PLEGRIDY were $690MM, including $455MM in US and $235MM in sales outside US. TYSABRI revenue was $463MM; $269MM in US and $195MM ex-US.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!